Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!

CAR-T Target Proteins

CAR-T Target Proteins

FITC-compatible CD19 Protein

CAT#: CAR-T001

Keywords: Human; C-His; Expi293

Inquiry

Human BCMA/TNFRSF17 Protein

CAT#: CAR-T002

Keywords: Human; C-His-Avi; Expi293

Inquiry

FITC-Labeled Human MSLN/Mesothelin Protein (C-His-Avi)

CAT#: CAR-T003

Keywords: Human; C-His-Avi; Expi293

Inquiry

FITC-Labeled Human MSLN/Mesothelin Protein (C-hFc)

CAT#: CAR-T004

Keywords: Human; C-hFc; Expi293

Inquiry

Human Siglec-2/CD22 Protein

CAT#: CAR-T005

Keywords: Human; C-His; Expi293

Inquiry

Human CD30/TNFRSF8 Protein

CAT#: CAR-T006

Keywords: Human; C-His-Avi; Expi293

Inquiry

Human Siglec-3/CD33 Protein

CAT#: CAR-T007

Keywords: Human; C-His-Avi; Expi293

Inquiry

Human CD7 Protein

CAT#: CAR-T008

Keywords: Human; C-His-Avi; Expi293

Inquiry

Biotinylated Human MSLN/Mesothelin Protein

CAT#: CAR-T009

Keywords: Human; C-hFc-Avi; Expi293

Inquiry

Human EGFR VIII Protein

CAT#: CAR-T010

Keywords: Human; C-His-Avi; Expi293

Inquiry

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

First
1
2
3

Alfa Cytology provides its clients with one-stop solutions to accelerate therapeutic discovery and development of brain tumors.

By Disease

Craniopharyngioma

Schwannoma (neuroma)

Pituitary Tumors

Choroid Plexus Tumors

By Molecule Type

Small Molecule Drug

Therapeutic Antibody

Immune Cell Therapy

Oncolytic Virotherapy

Vaccine Development

Contact Us

Copyright © 2024 Alfa Cytology. All rights reserved.